Release Date: October 19, 2023
Expiration Date: October 19, 2024
Time to Complete: 15 minutes
Format: Internet‐based Video
0.25 / AMA PRA Category 1 Credit TM
0.25 / CNE Contact Hour
This educational initiative will primarily target medical oncologists (and residents/fellows specializing in oncology) working in community settings within the United States who treat patients with NSCLC. Given the reliance upon the oncology team to ensure patient engagement, while also effectively monitoring and managing adverse events, the oncology care team will definitely benefit from this type of initiative (to include oncology nurses, nurse navigators, oncology nurse practitioners and physician assistants).
Statement of Purpose
The overall concept for this educational initiative for community oncologists is to address unmet educational needs and positively impact practice change behaviors by accelerating the dissemination of new information. This initiative will be delivered in a pragmatic format designed to provide relevant and actionable information to the target audience where they are already engaging - on social media platforms. Antidote will work with the faculty and thought leaders to identify and disseminate findings from new studies and recently-published data relevant to Non-small Cell Lung Cancer (NSCLC).
Upon completion of this educational activity, participants will be better able to:
- More confidently discuss the current state of the field related to include Next Generation Sequencing (NGS) testing for cancer and available NSCLC treatment options.
- Consider the evidence related to how to most effectively treat and manage patients with NSCLC.
This CME activity is supported by an unrestricted educational grant from Daiichi Sankyo.
Content Planning Faculty
This activity is provided by Antidote Education Company.
Physicians: Antidote Education Company is accredited with Commendation by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Antidote designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses: This nursing continuing professional development activity was approved by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation. Nurses may receive a maximum of 0.25 contact hour for completing the activity.
Method of Participation
- Register/Sign In.
- Read the learning objectives and disclosures.
- View the entire video.
- Complete post‐test with a score of 70% or better.
- Complete the evaluation and submit.
- A certificate will be emailed to you within 2 weeks.
For more information about the accreditation of this program, please contact Antidote Education Company at [email protected].
In accordance with The Standards for Integrity and Independence in Accredited Continuing Education promulgated by the Accreditation Council for Continuing Medical Education (“ACCME”), it is the policy of Antidote Education Company that all individuals in a position to control the content of an activity disclose all financial relationships with any ineligible company to Antidote prior to the activity. A relevant financial relationship is defined as any financial relationship in any amount occurring within the past 24 months with an ineligible company. A relevant financial relationship exists when an individual has an opportunity to affect CME content about products or services of an ineligible company with which he or she has a financial relationship. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Antidote has established mechanisms to mitigate any relevant financial relationships disclosed or otherwise identified to ensure independence in all of its educational activities. If, through the application of these mechanisms, an individual’s relevant financial relationships cannot be resolved, that individual is prohibited from participating in the activity in question in any manner.
The relevant financial relationships, if any, of the individuals in a position to control the content of this educational activity have been mitigated through Antidote’s conflict resolution mechanism. Nonetheless, the relevant financial relationships, if any, of each individual in a position to control the content of this educational activity have been disclosed to you in the following section of this handout entitled “Disclosures.” If an individual has no relevant financial relationships, that fact is also provided to you.
Charu Aggarwal, MD, MPH
Leslye M. Heisler Associate Professor for Lung Cancer Excellence
University of Pennsylvania
Dr. Aggarwal, speaker for this educational activity, is a Consultant for AstraZeneca, Blueprint Genetics, Celgene Corporation, Daiichi Sankyo/AstraZeneca, Eisai Co., Ltd., Genentech, Inc., Lilly, Merck & Co., Regeneron/Sanofi, and Shionogi Inc., and has been provided Research Funding (if PI or named investigator) from AstraZeneca/MedImmune LLC, Genentech/Roche, Incyte, MacroGenics, Inc., and Merck Sharp & Dohme.
Narjust Florez, MD
Associate Director of The Cancer Care Equity Program
Thoracic Medical Oncologist
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Dr. Florez, speaker for this educational activity, is an Advisor for AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Pfizer Inc., and Regeneron Pharmaceuticals, Inc.; received Research funding (if PI or named investigator) from Genentech, Inc.; and a Researcher for Mirati Therapeutics, Inc.
Howard (Jack) West, MD
Associate Professor, Medical Oncology
City of Hope Comprehensive Cancer Center
Vice President of Network Strategy, AccessHope
Los Angeles, CA
Dr. West, speaker for this educational activity, is a Consultant for AbbVie Inc., Amgen Inc., AstraZeneca, Daiichi Sankyo, Genentech/Roche Group, Gilead Sciences, Inc., Merck & Co., Mirati Therapeutics, Inc., Regeneron, Summit Therapeutics, Takeda Pharmaceutical Company, and a Speaker for AstraZeneca and Merck & Co.
Rahul Gosain, MD
Medical Director, Wilmot Cancer Center in Webster
Wilmot Cancer Institute - University of Rochester School of Medicine
Dr. Gosain, planner and speaker for this educational activity, is a Consultant for AstraZeneca and Gilead Sciences, Inc.
Rohit Gosain, MD
Chair of Medical Hematology/Oncology
UPMC Chautauqua Hospital
All of the relevant financial relationships listed for these individuals above have been mitigated.
Planners’ and Manager’s Disclosures
The following planners, content reviewer, and writer/editor have reported that they do not have any relevant financial relationships with ACCME-defined ineligible companies during the past 24 months: Rohit Gosain, MD; Matthew Fleming; Michael Fleming, MD; Laura Irvin, MHL, RN, BSN; and Emma Hitt Nichols, PhD.
Disclosure of Unlabeled Use
Antidote Education Company requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. This activity will not discuss any “off-label” substance(s)/product(s) not approved by the FDA.
The material presented at this course is being made available by Antidote Education Company for educational purposes only. This material is not intended to represent the only, nor necessarily best methods or procedures appropriate for the medical situations discussed, but rather is intended to present an approach, view, statement or opinion of the faculty which may be helpful to others who face similar situations. Opinions expressed in this activity are those of the faculty and not of Antidote. Every effort has been made to assure the accuracy of the data presented at this course. Physicians may care to check specific details prior to clinical application.